NIEMEYER, P., M. HANUS, J. BELICKAS, T. LÁSZLÓ, R. GUDAS, M. FIODOROVAS, A. CEBATORIUS, M. PASTUCHA, P. HOZA, K. MAGOS, K. IZADPANAH, Libor PAŠA, G. VÁSÁRHELYI, K. SISÁK, M. MOHYLA, C. FARKAS, O. KESSLER, S. KYBAL, R. SPIRO, A. KÖHLER, A. KIRNER, S. TRATTNIG and C. GAISSMAIER. Treatment of Large Cartilage Defects in the Knee by Hydrogel-Based Autologous Chondrocyte Implantation: Two-Year Results of a Prospective, Multicenter, Single-Arm Phase III Trial. Cartilage. THOUSAND OAKS: Sage, 2022, vol. 13, No 1, p. 1-14. ISSN 1947-6035. Available from: https://dx.doi.org/10.1177/19476035221085146.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Treatment of Large Cartilage Defects in the Knee by Hydrogel-Based Autologous Chondrocyte Implantation: Two-Year Results of a Prospective, Multicenter, Single-Arm Phase III Trial
Authors NIEMEYER, P., M. HANUS (203 Czech Republic), J. BELICKAS, T. LÁSZLÓ, R. GUDAS, M. FIODOROVAS, A. CEBATORIUS, M. PASTUCHA (203 Czech Republic), P. HOZA (203 Czech Republic), K. MAGOS, K. IZADPANAH, Libor PAŠA (203 Czech Republic, belonging to the institution), G. VÁSÁRHELYI, K. SISÁK, M. MOHYLA (203 Czech Republic), C. FARKAS, O. KESSLER, S. KYBAL, R. SPIRO, A. KÖHLER, A. KIRNER, S. TRATTNIG and C. GAISSMAIER.
Edition Cartilage, THOUSAND OAKS, Sage, 2022, 1947-6035.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30211 Orthopaedics
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 2.800
RIV identification code RIV/00216224:14110/22:00125638
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1177/19476035221085146
UT WoS 000777647800001
Keywords in English autologous chondrocyte implantation; cartilage repair; hydrogel; knee; large defects
Tags 14110711, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 19/7/2022 13:22.
Abstract
Objective: To evaluate the clinical outcome of a hydrogel-based autologous chondrocyte implantation (ACI) for large articular cartilage defects in the knee joint. Design: Prospective, multicenter, single-arm, phase III clinical trial. ACI was performed in 100 patients with focal full-thickness cartilage defects ranging from 4 to 12 cm2 in size. The primary outcome measure was the responder rate at 2 years using the Knee Injury and Osteoarthritis Outcome Score (KOOS). Results: Two years after ACI treatment, 93% of patients were KOOS responders having improved by ≥10 points compared with their pre-operative level. The primary endpoint of the study was met and demonstrated that the KOOS response rate is markedly greater than 40% with a lower 95% CI (confidence interval) of 86.1, more than twice the pre-specified no-effect level. KOOS improvement (least squares mean) was 42.0 ± 1.8 points (95% CI between 38.4 and 45.7). Mean changes from baseline were significant in the overall KOOS and in all 5 KOOS subscores from Month 3 (first measurement) to Month 24 (inclusive) (P < 0.0001). The mean MOCART (Magnetic Resonance Observation of Cartilage Repair Tissue) score after 24 months reached 80.0 points (95% CI: 70.0-90.0 points) and 92.1 points in lesions ≤ 5 cm2. Conclusions: Overall, hydrogel-based ACI proved to be a valuable treatment option for patients with large cartilage defects in the knee as demonstrated by early, statistically significant, and clinically meaningful improvement up to 2 years follow-up. Parallel to the clinical improvements, MRI analyses suggested increasing maturation, re-organization, and integration of the repair tissue.
PrintDisplayed: 22/8/2024 14:24